Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.230
-0.130 (-3.87%)
Jul 24, 2025, 11:51 AM - Market open
Rocket Pharmaceuticals Stock Forecast
RCKT's stock price has decreased by -86.83% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 13 analysts that cover Rocket Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $16.54, which forecasts a 412.07% increase in the stock price over the next year. The lowest target is $2.5 and the highest is $44.
Price Target: $16.54 (+412.07%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 17, 2025.
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 3 | 4 | 4 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jul 24, 2025 |
| UBS | UBS | Strong Buy Maintains $12 → $5 | Strong Buy | Maintains | $12 → $5 | +54.80% | Jun 17, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $34 → $11 | Strong Buy | Maintains | $34 → $11 | +240.56% | Jun 3, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $32 → $9 | Strong Buy | Maintains | $32 → $9 | +178.64% | May 28, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $30 → $8 | Buy | Maintains | $30 → $8 | +147.68% | May 28, 2025 |
Financial Forecast
Revenue This Year
n/a
from 249.83M
Revenue Next Year
n/a
EPS This Year
-2.26
from -2.73
EPS Next Year
-1.81
from -2.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 150.2M | 321.3M | 581.7M | ||
| Avg | 12.1M | 85.8M | 137.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -39.9% | 2,554.5% | 578.1% | ||
| Avg | -95.2% | 608.9% | 59.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.11 | -1.04 | 1.85 | ||
| Avg | -2.26 | -1.81 | -1.16 | ||
| Low | -2.53 | -2.36 | -1.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.